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MaBACKGROUND Coronary high-intensity plaques detected by noncontrast T1-weighted imaging may represent plaque
instability. High-intensity plaques can be quantitatively assessed by a plaque-to-myocardium signal-intensity ratio (PMR).
OBJECTIVES This pilot, hypothesis-generating study sought to investigate whether intensive statin therapy would
lower PMR.
METHODS Prospective serial noncontrast T1-weighted magnetic resonance imaging and computed tomography
angiography were performed in 48 patients with coronary artery disease at baseline and after 12 months of intensive
pitavastatin treatment with a target low-density lipoprotein cholesterol level <80 mg/dl. The control group consisted
of coronary artery disease patients not treated with statins that were matched by propensity scoring (n ¼ 48). The
primary endpoint was the 12-month change in PMR. Changes in computed tomography angiography parameters and
high-sensitivity C-reactive protein levels were analyzed.
RESULTS In the statin group, 12months of statin therapy signiﬁcantly improved low-density lipoprotein cholesterol levels
(125 to 70 mg/dl; p < 0.001), PMR (1.38 to 1.11, an 18.9% reduction; p< 0.001), low-attenuation plaque volume, and the
percentage of total atheroma volumeon computed tomography. In the control group, the PMR increased signiﬁcantly (from
1.22 to 1.49, a 19.2% increase; p < 0.001). Changes in PMR were correlated with changes in low-density lipoprotein
cholesterol (r ¼ 0.533; p < 0.001), high-sensitivity C-reactive protein (r ¼ 0.347; p < 0.001), percentage of atheroma
volume (r ¼ 0.477; p < 0.001), and percentage of low-attenuation plaque volume (r ¼ 0.416; p < 0.001).
CONCLUSIONS Statin treatment signiﬁcantly reduced the PMR of high-intensity plaques. Noncontrast T1-weighted
magnetic resonance imaging could become a useful technique for repeated quantitative assessment of plaque
composition. (Attempts at Plaque Vulnerability Quantiﬁcation with Magnetic Resonance Imaging Using Noncontrast
T1-weighted Technique [AQUAMARINE]; UMIN000003567) (J Am Coll Cardiol 2015;66:245–56) © 2015 by the
American College of Cardiology Foundation.m the *Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan; yDepartment of
rdiovascular Medicine, Saga University, Saga, Japan; zCardiovascular Center, Shin-Koga Hospital, Kurume, Japan; xDepartment
Radiology, National Cerebral and Cardiovascular Center, Suita, Japan; kPreventive Medicine and Epidemiologic Informatics,
nter for Cerebral and Cardiovascular Disease Information, National Cerebral and Cardiovascular Center, Suita, Japan; {Division
Coronary Artery Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; and the #Icahn
ool of Medicine at Mount Sinai, New York, New York. The present work was supported in part by a Grant-in-Aid for Scientiﬁc
search (B) [MEXT KAKENHI Grant Number 23591026], a Grant-in-Aid from the Japanese Ministry of Health, Labour, andWelfare
24-Junkanki-009], and funding from the Takeda Science Foundation and the Japan Cardiovascular Research Foundation. Dr.
rula has received research support from Philips Healthcare and GE Healthcare in the form of equipment grants to the insti-
ion. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Chun
an, PhD, served as Guest Editor for this paper.
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
nuscript received January 30, 2015; revised manuscript received April 21, 2015, accepted May 12, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
CAD = coronary artery disease
CMR = cardiac magnetic
resonance
CTA = computed tomography
angiography
HbA1c = glycosylated
hemoglobin
HDL-C = high-density
lipoprotein cholesterol
HIP = high-intensity plaque
hs-CRP = high-sensitivity
C-reactive protein
HU = Hounsﬁeld unit
IPH = intraplaque hemorrhage
IVUS = intravascular
ultrasound
LAP = low-attenuation plaque
LCL-C = low-density
lipoprotein-cholesterol
PCI = percutaneous coronary
intervention
PMR = plaque-to-myocardium
signal-intensity ratio
RI = remodeling index
TAV = total atheroma volume
T1WI = T1-weighted magnetic
resonance imaging
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246A coronary artery showing high-intensity plaque (HIP) on noncontrastT1-weighted magnetic resonance im-
aging (T1WI) has been reported to be high
risk because of its strong correlation with
positive remodeling and low attenuation
observed on computed tomography angiog-
raphy (CTA) or intravascular ultrasound
(IVUS) (1). The T1WI technique highlights
intraplaque components with short T1 as
having a high signal intensity. A necrotic
core with intraplaque hemorrhage (IPH)
or thrombus gives rise to a short T1 signal
(2,3). A plaque-to-myocardium signal-inten-
sity ratio (PMR)$1.4 during T1WImay be a sig-
niﬁcant predictor of major adverse cardiac
events in patients with coronary artery dis-
ease (CAD) (4). If coronary HIP with a high
PMR represents a high-risk plaque and a
greater likelihood of unfavorable outcomes,
then it is reasonable to propose that a quanti-
tative reduction in HIP may help plaque
stabilization.SEE PAGE 257Several randomized studies have demon-
strated the beneﬁts of statins in reducing
both mortality and the incidence of acute
coronary syndrome (ACS) (5–7). In addition
to reducing levels of serum low-densitylipoprotein-cholesterol (LDL-C), statins also may
contribute to plaque stability by reducing inﬂamma-
tion (8), improving endothelial function, (9), and
reinforcing the ﬁbrous cap (10,11); these effects alter
plaque volume and composition, both of which play
crucial roles in the progression to ACS (12,13). Serial
imaging studies suggest that statins favorably affect
the magnitude of the lipid-rich necrotic core (10,14),
but there are no prospective studies examining
the effect of intensive statin therapy on coronary
HIP or IPH. Hence, we undertook the prospectively
designed, open-label AQUAMARINE (Attempts at
Plaque Vulnerability Quantiﬁcation with Magnetic
Resonance Imaging Using Noncontrast T1-weighted
Technique) pilot study to investigate whether inten-
sive statin therapy could decrease the PMR of coro-
nary HIPs through its plaque-stabilizing effects.
METHODS
The AQUAMARINE pilot study was a prospective,
open-label, propensity score–matched study at 2 cen-
ters examining the effect of 12 months of pitavastatin
therapy (with target LDL-C levels <80 mg/dl) on thePMR and CTA measures in patients with CAD. The
primary endpoint was the change in the PMR of HIP
after intensive pitavastatin treatment. The secondary
endpoints were the change in CTA-measured indexes
(described below) and high-sensitivity C-reactive
protein (hs-CRP) levels as assayed by latex nephe-
lometry from fasting serum samples (SRL, Tokyo,
Japan).
All imaging and laboratory data were analyzed by
an independent attending physician and radiologist
at the National Cerebral and Cardiovascular Center
(Japan), including cardiac magnetic resonance (CMR)
and CTA measurements. These evaluators were blin-
ded to patient treatment status. This study was
approved by the institutional review board of the
National Cerebral and Cardiovascular Center and the
ethics committee of Shin-Koga Hospital. Written
informed consent was obtained from all enrolled
patients.
Between June 2009 and December 2011, 123
consecutive patients with CAD were initially screened
with CTA followed by CMR using noncontrast T1WI
(Figure 1). Patients were excluded if they had 1) a
history of treatment with any statin before enroll-
ment (n ¼ 25); 2) scheduled percutaneous coronary
intervention (PCI) (n ¼ 24); 3) an estimated glomer-
ular ﬁltration rate <60 ml/min/1.73 m2 (n ¼ 9);
4) severely calciﬁed coronary lesions detected by CTA
(n ¼ 7); 5) unstable angina pectoris (n ¼ 1); or 6) poor
CMR or CTA image quality (n ¼ 4). CAD was deﬁned as
a history of myocardial infarction or PCI, symptom-
atic angina pectoris or silent ischemia diagnosed with
stress myocardial scintigraphy, or coronary arterio-
graphy–veriﬁed coronary artery stenosis >25%, as
previously reported (4).
In the intensive therapy arm, 53 patients received
pitavastatin 4 mg/day to achieve an LDL-C level
<80 mg/dl (15). Of these patients, 5 needed to be
excluded: 1 patient had elevated creatine kinase
levels (although <5 times the upper limit of normal);
1 had recurrent abdominal pain; and 3 patients with-
drew consent, leaving 48 patients in the treatment
arm (Figure 1). CTA and CMR were performed at week
0 (baseline) and at 12 months (follow-up) after
pitavastatin administration.
For ethical reasons, the institutional review board
did not approve a study in which patients with CAD
would be randomized to no lipid-lowering statin
therapy. Therefore, the control group consisted of 133
CAD patients who underwent CTA and noncontrast
T1WI at baseline and 12 months of follow-up between
2008 and 2009. Of these patients, 84 patients who
did not receive statins or other LDL-lowering agents
(e.g., ezetimibe) were matched according to a
FIGURE 1 Flow Chart of the Study Patients
133 patients with CAD who
underwent CTA and non-contrast
T1WI in 2008 and 2009
No statin therapy and evaluated with
CTA and CMR at 12-month follow-up (n = 84)
Excluded (n=70)
History of treatment with any statin (n=25)
Scheduled PCI (n=24)
Estimated GFR <60 ml/min/1.73 m2 (n=9)
Severely calcified coronary lesions (n=7)
Unstable angina pectoris (n=1)
Poor CTA or CMR image quality (n=4)
Discontinued participation
in the study (n=5)
Withdrew consent (n=3)
Elevated creatine kinase (n=1)
Recurrent abdominal pain (n=1)Propensity score matching
Propensity score–matched
control group
(n = 48)
Statin group
(n = 48)
Follow-up at 12 months with
CTA and CMR
123 patients with CAD who
underwent CTA and non-contrast
T1WI between 2009 and 2011
Intensive statin treatment
(n = 53)
This chart depicts the enrollment, exclusion, and matching of patients with coronary artery disease (CAD) who became part of the statin group
or the propensity-matched control group. CMR ¼ cardiac magnetic resonance; CTA ¼ computed tomography angiography; GFR ¼ glomerular
ﬁltration rate; PCI ¼ percutaneous coronary intervention; T1WI ¼ T1-weighted imaging.
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247propensity score on the basis of age, sex, body mass
index, systolic blood pressure, history of diabetes
mellitus, hypertension, dyslipidemia, and current
smoking, as well as baseline LDL-C, total cholesterol,
high-density lipoprotein cholesterol (HDL-C), tri-
glycerides, glycosylated hemoglobin (HbA1c) levels,
hs-CRP, medications, and PMR. Subsequently, 48
propensity score–matched control subjects were
included in the study. Control patients not on a statin
declined any form of lipid-lowering pharmacotherapy
and insisted on dietary intervention alone (n ¼ 39),
had a history of an adverse event associated with
statin therapy (n ¼ 6), or received ethyl icosapentate
(n ¼ 26) or bezaﬁbrate or fenoﬁbrate (n ¼ 13).
CMR IMAGING AND ANALYSIS. CMR imaging con-
sisted of magnetic resonance coronary angiography
and plaque T1WI using a commercial 1.5-T magnetic
resonance imager (Intera, Philips Medical Systems,
Best, the Netherlands). The procedures used to ac-
quire magnetic resonance images in this study have
been previously described (4).
The methods that we used to evaluate plaque
images also have been described previously (1,4).Brieﬂy, 2 independent experienced investigators who
were unaware of the patient data used the T1WI to
calculate the PMR at the central core laboratory. The
highest signal intensity detected in each plaque was
considered the PMR value for that plaque in the
segment-based analysis. On patient-based analysis,
the highest PMR among the coronary plaques was
considered the PMR for that patient. Examination of
coronary segments was limited to 1 to 3, 5 to 7, and
11 to 13, on the basis of recommendations from
the American Heart Association (16). To conﬁrm that
the location of an observed HIP corresponded to the
presence of a coronary plaque, we used both cross-
sectional and curved multiplanar reformation CTA
images. Additionally, we used coregistration images
to facilitate conﬁrmation of the anatomic position of
high-intensity lesions on T1WI and the coronary
vessel on magnetic resonance coronary angiography
using commercially available software (Virtual Place
Raijin Workstation, AZE, Tokyo, Japan) (4). Regarding
PMR quantiﬁcation of coronary plaques without HIP,
when CTA showed >20% coronary stenosis in seg-
ments 1 to 3, 5 to 7, or 11 to 13, the PMR of the target
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248lesion was measured using the coregistration method
described previously. The intraobserver intraclass
correlation coefﬁcient was 0.94 (95% conﬁdence in-
terval [CI]: 0.80 to 0.98). The interobserver intraclass
correlation was 0.88 (95% CI: 0.73 to 0.95). All cor-
relation coefﬁcients for the PMR were >0.8, with
narrow CIs, indicating good intraobserver and inter-
observer agreement (4).
CTA SCANNING AND ANALYSIS. Coronary CTA was
performed using a LightSpeed VCT scanner (GE
Healthcare, Milwaukee, Wisconsin). The procedures
used to acquire CTA images have been previously
described (1). We used the same protocol and same
dose of contrast medium at both baseline and follow-
up CTA in each patient.
We examined coronary segments with >20%
diameter stenosis in segments 1 to 3, 5 to 7, and 11 to
13. Quantitative lesion analysis was performed using
software that facilitates plaque and lumen volume
measurement (Ziostation2, Ziosoft, Tokyo, Japan).
Parameters assessed included: 1) plaque volume;
2) remodeling index (RI) with plaques having an
RI $1.10 considered to be within a positive remodeled
artery (17); and 3) Hounsﬁeld unit (HU), as coded
by the software into low-attenuation plaques
(LAPs) (<30 HU), intermediate attenuation plaquesTABLE 1 Baseline Characteristics
Unmatched Groups
Statin Group
(n ¼ 48)
Control Group
(n ¼ 84)
Age, yrs 62.6 65.0
Male 44 (92) 71 (85)
Hypertension 34 (71) 61 (73)
Current smoker 18 (38) 44 (52)
Dyslipidemia 40 (83) 48 (57)
Diabetes mellitus 30 (63) 42 (50)
BMI, kg/m2 24.8  3.5 24.1  3.0
SBP, mm Hg 143  18 145  22
TC, mg/dl 208  34 195  31
LDL, mg/dl 125  25 114  26
HDL, mg/dl 50  13 51  14
TG, mg/dl 179  95 155  107
HbA1c, % 6.1  1.2 6.3  1.7
hs-CRP, mg/l 1.19 (0.65, 3.31) 1.04 (0.43, 2.60)
PMR 1.38 (1.20, 1.50) 1.20 (1.03, 1.44)
Medications
Aspirin 43 (90) 74 (88)
Beta-blocker 28 (58) 42 (50)
ACEI or ARB 21 (44) 35 (42)
Values are mean  SD, n (%), or median (ﬁrst quartile, third quartile).
ACEI¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker
C-reactive protein; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; P
TC ¼ total cholesterol; TG ¼ triglycerides.(30 to 150 HU), calciﬁed plaques (351 to 1,000 HU),
and lumen (151 to 350 HU) by color. The volume
of each component was measured (17,18). Each
lesion was analyzed for total atheroma volume (TAV),
lumen volume, RI, LAP volume, percentage of total
atheroma volume, and percentage of LAP volume.
DATA AND STATISTICAL ANALYSIS. We used
propensity-score matching to adjust for the non-
random absence of statin therapy after CMR and CTA.
The propensity score was estimated by using probit
regression models (19,20), with pre-evaluation statin
administration as the outcome. It included baseline
clinical history and presentation characteristics
as predictors (covariates are listed in Table 1).
A propensity score–matched cohort was constructed
with statin receivers and nonreceivers matched on a
1:1 basis by a nearest-neighbor matching method
within a caliper of 0.05 of the propensity score, using
STATA’s psmatch2 software (StataCorp LP, College
Station, Texas) for propensity-score matching (21).
Next, 48 patients were selected for the control group.
because we previously identiﬁed a PMR of 1.4 as the
optimal cutoff value for predicting coronary events
(4), both the treatment and control groups were
further classiﬁed according to the PMR cutoff value of
either $1.4 or <1.4.Propensity Score–Matched Groups
p Value
Statin Group
(n ¼ 48)
Control Group
(n ¼ 48) p Value
0.145 62.6 62.7 0.945
0.290 44 (92) 45 (94) 0.782
0.843 34 (71) 35 (73) 0.897
0.107 18 (38) 19 (40) 0.896
0.002 40 (83) 38 (79) 0.712
0.204 30 (63) 29 (60) 0.806
0.192 24.8  3.5 24.6  2.8 0.815
0.458 143  18 144  20 0.784
0.020 208  34 211  38 0.740
0.006 125  25 126  21 0.900
0.754 50  13 51  10 0.748
0.190 179  95 167  81 0.592
0.459 6.1  1.2 6.1  1.1 0.902
0.881 1.19 (0.65, 3.31) 1.12 (0.33, 3.42) 0.984
0.225 1.38 (1.20, 1.50) 1.22 (1.01, 1.56) 0.922
1.000 43 (90) 44 (92) 1.000
0.372 28 (58) 21 (44) 0.220
0.856 21 (44) 17 (35) 0.532
; BMI¼ body mass index; HbA1c¼ glycosylated hemoglobin; hs-CRP ¼ high-sensitivity
MR ¼ plaque-to-myocardium signal-intensity ratio; SBP ¼ systolic blood pressure;
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249Continuous variables are presented as mean  SD
for normally distributed variables; they were
compared using the Student t test. Non-normally
distributed variables are presented as median (inter-
quartile range). They were compared using a Mann-
Whitney U test. Categorical baseline variables were
compared using the Fisher exact test or the chi-
square test as appropriate. Given that plaque lumen
volume, TAV, LAP volume, and RI were not normally
distributed at baseline, the Wilcoxon signed rank test
was used for comparisons involving CTA indexes and
PMR between the statin and control groups. Because
segments within patients were not independent,
predicted PMRs were obtained from a linear mixed
model with random intercepts in which each patient
was considered as the hierarchy. Two-by-two re-
peated measures were included in the model with
the group (statin vs. control) by time (baseline to
follow-up) interaction term adjusted for correlations
between individuals and segments. The xtmixed
command in STATA was used for modeling.
We used linear regression analysis to assess the
relationship between the percentage of change in the
PMR during follow-up and the percentage of change
in LDL-C, HDL-C, logarithmic hs-CRP, HbA1c, per-
centage of TAV, and percentage of LAP volume. Sta-
tistical signiﬁcance was deﬁned as p < 0.05. All
analyses were performed with SPSS for Windows,
version 12.0 (SPSS Japan Inc., Tokyo, Japan) and
STATA 13 (StataCorp).
RESULTS
Baseline clinical characteristics of the unmatched
cohort (Table 1) showed signiﬁcant differences in the
prevalence of dyslipidemia as well as total cholesterol
and LDL-C levels. There were 37 HIP-positive (PMR
>1.0) patients (77%) in the intensive-statin group,
consisting of 17 with a PMR $1.4 and 20 with a PMRTABLE 2 Changes in Laboratory Data
Statin Group Propensity
Baseline Follow-Up p Value Baseline
Lipid proﬁles
TC, mg/dl 208  34 152  25 <0.001 211  38
LDL, mg/dl 125  25 70  11 <0.001 126  21
HDL, mg/dl 50  13 52  13 0.945 51  10
TG, mg/dl 179  95 138  80 <0.001 167  81
HbA1c, % 6.1  1.2 6.2  1.0 0.828 6.1  1.1
hs-CRP, mg/l 1.19 (0.65–3.31) 0.62 (0.33–1.18) <0.001 1.12 (0.33–3.4
Values are mean  SD or median (interquartile range). *Percentage of change from bas
Abbreviations as in Table 1.between 1.0 and 1.4. Among the 48 control patients, 32
(67%) were HIP positive (PMR $1.4, n ¼ 11; PMR 1.0 to
1.4, n ¼ 21). As for the matched cohorts, the 2 groups
were well matched at baseline, with no statistically
signiﬁcant differences in age, male sex, conventional
coronary risk factors, systolic blood pressure, lipid
proﬁle, HbA1c, hs-CRP levels, medications used, and
PMR between the statin and control groups.
Table 2 shows the comparison of laboratory data at
baseline and 12 months (mean: 13.2  0.6; range: 12 to
15 months) in the 48 patients who completed inten-
sive pitavastatin treatment and the 48 propensity
score–matched control patients. In the statin group,
mean LDL-C decreased from 125  25 mg/dl to 70  11
mg/dl (percentage of change from baseline: 42.1 
14.1%; p < 0.001), whereas there was no signiﬁcant
reduction in LDL-C in the control patients (from 126 
21 mg/dl to 121  25 mg/dl; percentage change from
baseline: 3.1  18%; p ¼ 0.789). In the statin group,
total cholesterol and triglycerides also decreased
signiﬁcantly by the end of follow-up (percentage of
change from baseline: 24.8  14.4%; p < 0.001;
and 22.7  35.8%; p < 0.001, respectively). Also, hs-
CRP levels were signiﬁcantly reduced in the statin
group (from 1.19 [0.65 to 3.31] mg/l to 0.62 [0.33 to
1.18] mg/l; 46.7  32.2%; p <0.001), but there was no
signiﬁcant change in the control group (from 1.12
[0.33 to 3.42] mg/l to 1.16 [0.48 to 3.58] mg/l; 2.0 
21.0%; p ¼ 0.773). HbA1c and HDL-C levels did not
change signiﬁcantly during follow-up in either group.
Figure 2 shows the changes in individual-level
(Figures 2A and 2B) and group-level data on the PMR
(Figures 2C and 2D), the primary efﬁcacy endpoint.
The baseline PMR was comparable (statin group: 1.38
[1.20 to 1.50] vs. control group: 1.22 [1.01 to 1.56]; p ¼
0.922). At 12 months, the PMR was signiﬁcantly lower
in the statin group (1.11 [1.02 to 1.25]; 18.9  11.1%
reduction from baseline; p < 0.001) compared with
an increase in the control group (1.49 [1.18 to 1.96];Score–Matched Control Group Comparison*
Follow-Up p Value Statin Group Control Group p Value
198  34 0.041 24.8  14.4 4.8  23 <0.001
121  25 0.789 42.1  14.1 3.1  18 <0.001
48  11 0.269 4.8  14.0 5.4  19 0.085
158  66 0.244 22.7  35.8 5.1  28 0.021
6.2  1.1 0.896 0.6  8.5 1.1  10 0.376
2) 1.16 (0.48–3.58) 0.773 46.7  32.2 2.0  21.0 <0.001
eline over 1 year in the statin versus control group.
FIGURE 3 Changes in Predicted PMR
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FIGURE 2 Comparisons of Change in PMR (Patient-Based Analysis)
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was observed in the percentage of change in PMR from baseline between the 2 groups. B/L ¼ baseline; F/U ¼ follow-up.
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25019.2  13.2% elevation from baseline; p < 0.001)
(Figures 2C and 2D). A signiﬁcant net difference was
observed in the percentage of change in the PMR from
baseline between the 2 groups (p < 0.001) (Figure 2D).
PMRs at baseline and follow-up stratiﬁed by statin
treatment status and adjusted for individual-level
correlations between segments estimated in a linear
mixed model are summarized in Figure 3 and Online
Table 1. The effect of statin treatment status and the
time-by-group interaction term were signiﬁcant
(p ¼ 0.008 and p < 0.001, respectively). Baseline
PMR values were similar in the statin and control
groups (p ¼ 0.241). During follow-up, PMR values
were 0.313 lower in the statin group than in the
control group (95% conﬁdence interval: 0.401
to 0.225; p < 0.001). PMR values decreased in the
statin group but increased in the control group dur-
ing follow-up (p < 0.001). The percentage of change
in the PMR was positively correlated with the per-
centage of change in LDL-C and logarithmic hs-CRP
(r ¼ 0.533; p < 0.001, and r ¼ 0.347; p < 0.001,
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251respectively) (Figures 4A and 4B), but not with the
percentage of change in HDL-C or HbA1c (data not
shown).
SEGMENT-BASED ANALYSIS. We analyzed 768 seg-
ments in 96 subjects. In the segment-based CMR
analysis, 519 segments were excluded because they
either contained lesions scheduled for PCI (18 seg-
ments), were previously treated with PCI and stent-
ing (11 segments), had poor imaging quality near
stents (48 segments), or had no signiﬁcant coronary
plaques with >20% stenosis identiﬁed by CTA (442
segments). The remaining 249 segments were studied
and divided into 4 groups according to the cutoff
PMR of 1.4 for predicting coronary events on the basis
of our previous study (4): statin group/PMR $1.4
(25 segments), statin group/PMR <1.4 (111 segments),
control group/PMR $1.4 (19 segments), and control
group/PMR <1.4 (94 segments). Figure 5 shows the
changes in the PMR for each segment and summa-
rizes the percentage of change in the PMR from
baseline in these 4 groups. In the statin group, the
percentage of reduction in the PMR from baselineFIGURE 4 Correlations Between Change in the PMR and Plaque-Rel
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Signiﬁcant positive correlations were seen between the percentage of c
the percentage of change in low-density lipoprotein cholesterol (LDL-C
percentage of total atheroma volume (C); and percentage of low attenuwas greater for PMR $1.4 plaques than PMR <1.4
plaques (19.0  12.1% vs. 7.8  11.3%; p < 0.001). In
the control group, however, the percentage of in-
crease in the PMR from baseline was higher for
PMR $1.4 plaques (19.7  15.1% vs. 12.0  11.0%;
p ¼ 0.037).
The 249 segments used in the segment-based
analysis of change in the PMR were analyzed using
CTA (Table 3). In the statin group, signiﬁcant changes
were observed in LAP volume, percentage of TAV,
and percentage of LAP volume, whereas TAV, lumen
volume, and RI did not signiﬁcantly change after
statin treatment. In the control group, TAV and LAP
volume were higher at follow-up but not statistically
signiﬁcant (p ¼ 0.057 and p ¼ 0.091, respectively);
lumen volume, percentage of TAV, percentage of LAP
volume, and RI did not change signiﬁcantly from
baseline. Overall, there were signiﬁcant positive cor-
relations between the percentage of change in the
PMR and TAV (Figure 4C) and LAP volume (Figure 4D).
Representative CMR and CTA images in the statin
and control groups are shown in Figures 6 and 7,
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Abbreviations as in Figure 2.
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252DISCUSSION
The major ﬁndings of this pilot study include the
following: 1) the PMR of coronary HIP was lowered
by statin therapy, which was also associated with
decreases in LDL-C and hs-CRP as well as a
decrease in the percentage of TAV and percentage
of LAP volume as evaluated by CTA; 2) the per-
centage of change in the PMR was greater in the
statin group with PMR $1.4 segments; and 3) inres
Statin Group Propensity Sc
Baseline Follow-Up p Value Baseline
195.2 (126.1–255.2) 167.8 (118.2–230.3) 0.078 216.6 (153.9–285.3
203.9 (135.0–261.8) 201.7 (135.5–265.1) 0.460 197.2 (129.0–296.5
, mm3 31.2 (15.2–59.5) 23.3 (10.1–43.8) 0.007 23.7 (15.6–39.6)
53.6 (39.7–59.4) 46.9 (35.1–59.2) 0.047 55.3 (51.3–60.5)
19.3 (11.3–24.9) 17.0 (8.2–21.1) <0.001 22.1 (19.3–26.5)
1.24 (1.06–1.40) 1.21 (1.14–1.35) 0.145 1.21 (1.11–1.38)
artile range) or mean  SD. *Percentage of change from baseline over 1 year in the statin
raphy angiography; HU ¼ Hounsﬁeld unit; LAP ¼ low-attenuation plaque; TAV ¼ total athethe control group, which did not receive statins or
other LDL-lowering agents, the PMR was higher at
12 months, especially in patients who had HIP
with PMR $1.4. The present study suggests the
feasibility of using serial CMR examinations using
noncontrast T1WI in clinical trials designed to
assess changes in coronary plaque characteristics
(Central Illustration).
Observations from carotid plaque magnetic reso-
nance imaging and histopathological validationore–Matched Control Group Comparison*
Follow-Up p Value Statin Group Control Group p Value
) 244.1 (144.3–340.6) 0.057 5.0  26.0 12.4  25.0 0.028
) 189.5 (121.8–247.8) 0.095 3.5  21.0 3.9  13 0.941
25.8 (15.7–45.2) 0.091 12.8  18.0 8.3  14.2 0.004
56.9 (52.5–64.3) 0.381 4.6  13.6 3.1  11.0 0.108
24.5 (19.7–26.1) 0.277 11.0  23.4 9.9  10.1 <0.001
1.23 (1.15–1.41) 0.151 2.4  9.4 1.7  10.1 0.138
versus control group.
roma volume.
FIGURE 6 PMR Regression With Statin Treatment
Baseline
12 months
A B
C D
A high-intensity plaque (HIP) with a PMR of 1.68 is observed in the proximal segment of the left anterior descending artery (LAD) at baseline
(A, yellow dotted circle). This HIP corresponds to the low-density coronary plaque with positive remodeling in the proximal portion of the LAD
on CTA (B). Cross-sectional CTA images of this HIP lesion show positive remodeling with low attenuation plaque (LAP) (a, b, c). After 12 months
of intensive statin treatment, PMR decreased to 1.08 (C, yellow dotted circle). CTA at follow-up shows a decrease in LAP volume (D, d, e, f).
Abbreviations as in Figures 1 and 2.
J A C C V O L . 6 6 , N O . 3 , 2 0 1 5 Noguchi et al.
J U L Y 2 1 , 2 0 1 5 : 2 4 5 – 5 6 Statin and High-Intensity Plaques on CMR
253studies (2,3,22), as well as studies using optic coher-
ence tomography (23) or specimens obtained through
an aspiration catheter during PCI after ACS (24)
suggest that a coronary HIP may represent IPH and
thrombus formation. Kawasaki et al. (1) systemati-
cally evaluated the components of HIPs in patients
undergoing CTA and IVUS. Coronary HIPs were
closely correlated with IVUS attenuation, as well as
with positive vascular remodeling and lower CT
density on CTA. The estimation of HIP-PMR provides
a useful quantitative measure that can be repeatedly
analyzed without the need for radiation exposure,
contrast agents, or invasive procedures (1,4). There-
fore, it is reasonable to use HIP-PMR for the serial
evaluation of plaque characterization, especially in
response to plaque-modifying agents.
Numerous carotid magnetic resonance studies have
demonstrated the critical role of IPH in plaque insta-
bility (25–27) and acute carotid vascular events (28).
Statin therapy has been posited to prevent neo-
vascularization (29) and limit the cholesterol content
of red blood cell membranes (30) and the phospholipid
ratio (31). Carotid IPH was less frequently observed in
patients on statins before endarterectomy (32), andthe use of statins before a transient ischemic attack or
stroke was negatively associated with the presence of
IPH (33). On the other hand, statin therapy has been
associated with a decrease in the percentage of LAP
volume as assessed by CTA (18). Komukai et al. (11) and
Hattori et al. (10) demonstrated that stain-induced
optical coherence tomography–veriﬁed increases in
ﬁbrous cap thickness were associated with decreases
in serum atherogenic lipoproteins and inﬂammatory
biomarkers. This suggests that statin therapy modiﬁes
plaque phenotype including its lipid-rich necrotic
core, ﬁbrous cap, and IPH, which in turn might have
reduced PMR values in our study. Future studies
should investigate whether the effect of statins on
HIPs, as monitored by noninvasive CMR, is also asso-
ciated with reductions in the risk of clinical events.
In our segment-based analysis, the degree of PMR
attenuation after statin treatment was signiﬁcantly
greater in the high versus low PMR groups.
Conversely, the magnitude of PMR increase was
signiﬁcantly greater in control patients with PMR
$1.4 segments than control patients with PMR <1.4
segments (Figure 5). Taken together with our previous
study demonstrating that coronary lesions with
FIGURE 7 PMR Progression in the Control Group
Baseline
12 months
A B C
D E F
Noncontrast T1-weighted imaging at baseline does not show any HIPs. The PMR was 0.92 in a lesion in the proximal segment of the right
coronary artery (A, yellow dotted circle, and B), which corresponds to a minor coronary plaque on CTA (C, a, b, c). However, after 12 months, a
representative HIP was observed at the same lesion in the right coronary artery (D, yellow dotted circle; E, yellow arrow), accompanied by
an increase in the PMR to 1.35. CTA shows signiﬁcant progression of coronary plaque morphology (F, d, e, f). Abbreviations as in Figures 2 and 6.
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254PMR $1.4 are at signiﬁcantly higher risk of subse-
quent ACS (4), the present ﬁndings indicate that
coronary lesions with PMR $1.4 may be associated
with accelerated plaque instability as well as
increased signal intensity, which may reﬂect an in-
crease in the volume of the necrotic core with IPH.
This supports recent ﬁndings that fateful plaques
are usually large with large necrotic cores (34).
However, increases in the PMR were observed
even in PMR <1.4 segments (12.0% increase from
baseline) (Figure 5), which are considered at lower
risk of coronary events on the basis of our previous
study (4). This suggests that even HIP with PMR <1.4
might evolve into a high-risk plaque during follow-
up. Given that atherosclerosis is a dynamic process,
our focus must remain on the entire disease process
(35). Early identiﬁcation of patients with HIP
regardless of stenosis severity or plaque burden may
prove valuable in the risk stratiﬁcation of patients
with CAD or multiple cardiovascular risk factors,
including diabetes mellitus. Additionally, the pre-
sent study proposes that noncontrast T1WI can
potentially be used for comparing plaque character-
istics at different time points and may assist in
assessing the efﬁcacy of antiatherosclerotic phar-
macological interventions.STUDY LIMITATIONS. As an observational study with
a small number of patients examined, there may be
inherent ﬂaws related to selection bias, spurious ob-
servations, unmeasured covariates, and nonrandom
allocation to treatment. However, we sought to
minimize these issues by using a propensity model
for multivariate analysis and added a summary of
coronary events in the 2 groups during follow-up on
the basis of an exact logistic regression analysis
(Online Table 2). These data suggest that patients
with HIPs seem to be at a higher risk of future coro-
nary events. Second, because plaque measurements
using CTA were performed semiautomatically, there
is a possibility of measurement error. Third, intensive
statin therapy did not change TAV and vessel RI as
detected by CTA in this study. This was inconsistent
with previous IVUS studies demonstrating that
intensive statin treatment induces reductions in TAV
as well as an absolute decrease in vessel RI (15,36).
CTA has lower spatial resolution than IVUS for the
measurement of plaque volume, which may in part be
related to these inconsistencies. Finally, Noyes et al.
(37) reported that plaque regression occurred after an
average of 19.7 months of statin treatment. Because
target LDL-C levels in this study were comparable
with other intensive statin IVUS studies (15,36), mean
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Noguchi, T. et al. J Am Coll Cardiol. 2015; 66(3):245–56.
Statin therapy reduces the plaque-to-myocardium signal intensity ratio (PMR) of coronary high-intensity plaque (HIP) through its plaque-stabilizing effects in
association with decreases in low-density lipoprotein cholesterol, high-sensitivity C-reactive protein (hs-CRP), and low attenuation plaque (LAP) volume.
In contrast, the PMR in the control group increased without signiﬁcant morphological changes detected by computed tomography angiography measures.
CMR ¼ cardiac magnetic resonance; IPH ¼ intraplaque hemorrhage; T1WI ¼ T1-weighted imaging.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: HIPs detected by
noncontrast T1WI are associated with ischemic coronary events.
TRANSLATIONAL OUTLOOK: Further studies are needed to
verify the clinical utility of adjusting the intensity of statin therapy
based on plaque intensity values assessed by CMR to reduce the risk
of coronary events.
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255changes in plaque volume and PMR at 1 year of
follow-up were acceptable. However, studies of
serial changes in the PMR of HIP beyond 1 year might
provide additional insights.
Most importantly, HIP assessment may be more
conveniently possible in Japanese subjects by virtue
of the body habitus and its applicability elsewhere
has yet to be determined. Therefore, the ﬁndings
and proposals from the study are considered hy-
pothesis generating.
CONCLUSIONS
The present study demonstrates that intensive
statin therapy reduces HIP-PMR identiﬁed by non-
contrast T1WI, which may represent a useful method
for quantitatively monitoring changes in plaque
vulnerability.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Teruo Noguchi, Department of Cardiovascular Medi-
cine, National Cerebral and Cardiovascular Center,
5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan.
E-mail: tnoguchi@hsp.ncvc.go.jp.
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